Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • shazzle
    Junior Member
    • Mar 2010
    • 3

    Quantifying trascript levels using RNA-seq

    Hi guys,

    I thought of asking this:

    1. Can we get sequencing data of a certain mrna from RNA-seq, say from heart and muscle, and use it to quantify and make conclusion about transcript levels in heart and muscle? Is it conclusive, i mean, wouldnt there be noise to take care of and some statistics to normalise the levels of capture on the mrna?

    2. If 1. is possible, can we extend the quantification theory to ChIP-seq ie. measuring TF levels in cancer/non-cancer groups?

    Thanks!
  • spenthil
    Member
    • Sep 2009
    • 44

    #2
    I am no way qualified to answer this question, but can point you to two papers that I have been meaning to read that do cover this:



    Pay particular attention to the idea of "5' bias" and random priming bias - which I think are the biggest problems with current techniques. Of particular note is a comment in the nature paper:
    RNA fragmentation before copying would also be expected to greatly reduce 5' bias. This protocol gave better overall uniformity than protocols without RNA fragmentation (Supplementary Fig. 1), although some residual and reproducible nonuniformity clearly persists for randomly primed substrates that was not observed in other kinds of Illumina sequencing substrates handled simultaneously, such as chromatin immunoprecipitation sequencing (ChIPSeq) samples
    --
    Senthil Palanisami

    Comment

    • malachig
      Senior Member
      • Aug 2010
      • 117

      #3
      RNA-Seq can certainly be used to quantify transcripts and compare between tissues. If your RNA is of high quality and your libraries are sequenced to sufficient depth the outcome is likely to be more reliable and less noisy than microarrays. I worked with microarrays for several years and with RNA-Seq for the last two years. Initially RNA-Seq has some growing pains but in my opinion it now beats microarrays hands down. It does not rely on prior knowledge of gene annotations and it has a better signal-to-noise ratio, sensitivity and specificity (if you have enough library depth). Furthermore, in our validations of expression and differential expression estimates from RNA-Seq we found the results to be highly comparable to qPCR.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      30 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      23 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      212 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      78 views
      0 reactions
      Last Post SEQadmin2  
      Working...